HOSP Partners are organizations that align with the commitment and advocacy efforts to improve patient outcomes and to innovate patient care through the integrated specialty pharmacy model. These organizations understand the value of collaboration in the advancements in research, advocacy, and education.
To learn more about the HOSP Partners, click on the logo below to preview their profile that provides information on their organization.
Since its founding 20 years ago, Alnylam has led the translation of RNA interference (RNAi) into a new
class of approved and investigational medicines for rare genetic, cardio-metabolic, hepatic infectious,
and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi
therapeutics are a clinically validated approach for the treatment of rare diseases with unmet medical
need and prevalent diseases. Alnylam is headquartered in Cambridge, MA. For more information,
please visit www.alnylam.com.
Company URL: www.alnylam.com
Email: [email protected]